Acute graft-versus-host disease
Conditions
Interventions
Case series:Ruxolitinib and low-dose corticosteroid
Sponsors
Blood Diseases hospital, Institute of Hematology, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients receiving allogeneic hematopoietic stem cell transplantation and acute graft-versus-host disease of grade II-IV were diagnosed after transplantation by clinical or biopsy confirmation; 2. Patients who can swallow tablets; 3. Patients with age >= 15 years old and < 65 years old are not limited to men and women. 4. For patients who have to sign the informed consent form before the start of the research procedure, the informed consent form shall be signed by the patient himself or his immediate family member for patients aged 18 and above; the informed consent form shall be signed by the legal guardian for children and adolescents under the age of 18.
Exclusion criteria
Exclusion criteria: 1. Patients with DLI or induced graft-versus-host disease after first intervention; 2. Patients with uncontrollable active infection; 3. Patients with overlap syndrome or chronic GVHD; 4. Patients who are allergic or intolerable to ruxolitinib. 5. Within one week patients who need to use more than 1mg/kg/d methylprednisolone for reasons other than graft-versus-host disease; 6. Patients who need to use other JAK inhibitors for other reasons after transplantation; 7. Patients who have participated in other clinical trials within 1 month; 8. Suffering from mental disorders or other conditions and unable to meet the requirements of research, treatment and monitoring; 9. Pregnant patients or patients who can not take appropriate contraceptive measures during treatment; 10. The researcher judges that there are other factors that are not suitable for participating in the study, or participating in the study will bring great risks to the patients;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR of aGVHD; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;RFS;RR;TRM;T cell subsets;levels of the cytokines;Treatment-emergent adverse events; | — |
Countries
China
Contacts
Public ContactJiang Erlie
Blood Diseases Hospital, Institute of Hematology, Chinese Academy of Medical Sciences
Outcome results
None listed